Hematology/Oncology and Blood & Marrow Transplant
Health Sciences Associate Clinical Professor
Skaggs School of Pharmacy and Pharmaceutical Sciences
Dr. Saunders is a Board Certified Oncology Pharmacist working in the Experimental Therapeutics/Precision Medicine and Blood & Marrow Transplant clinics at Moores Cancer Center (MCC). Prior to joining the faculty at SSPPS in August 2014, Dr. Saunders was a Clinical Pharmacy Specialist at MD Anderson Cancer Center (MDACC) and practiced in the department of Stem Cell Transplant and Cellular Therapy (SCTCT) for 6 years.
B.S. in Microbiology & Molecular Genetics, University of California, Los Angeles (2001); Pharm.D., University of California, San Francisco (2006); PGY1 Pharmacy Practice Residency, University of California, San Francisco (2006-2007); PGY2 Oncology Pharmacy Practice Residency, MD Anderson Cancer Center (2007- 2008); Board Certified in Oncology Pharmacy (2009).
Awards and Honors:
Phi Lambda Sigma Leadership Society, Beta Beta chapter.
Dr. Saunders is an active member of the Hematology Oncology Pharmacists Association (HOPA) and has served as a member of the Session Proposal Task Force (2011-2014), Research Abstract Review Work Group (2014-2015), Vice-chair of the Entry-level Competencies in Hematology/Oncology Pharmacy Practice for Graduates of the Doctor of Pharmacy Degree and Post-Graduate Year 1 Pharmacy Practice Residency Task Force for HOPA (2016-2017), Chair of the BCOP Conference Program Planning Committee as Chair (2017-2018), and currently serves on the BCOP Oversight committee as Vice-chair. Dr. Saunders is also a member of the American Society of Blood and Marrow Transplantation (ASBMT) Pharmacy Special Interest Group and has served on the Advocacy & Policy Working Committee as the chair (2015-2016). She also is an active member of the SWOG (Southwestern Oncology Group) Pharmaceutical Sciences Committee and Drug Information Subcommittee. Dr. Saunders also is a member of the NCCN Chemotherapy Order Templates committee.
At SSPPS, Dr. Saunders has served on several committees, including the Committee on Educational Policy, the Co-curricular Task Force. She currently is a member of the Pfizer/UCSD Pharmacology/Oncology Fellowship committee and the Admissions Committee. She is the first oncology clinical pharmacist in the outpatient clinics at MCC and has collaborated with cancer center and pharmacy leadership to expand oncology clinical pharmacy services at MCC. She also serves as a member of the Institutional Review Board- Oncology and is a guest member of the Oncology Pharmacy & Therapeutics subcommittee at MCC.
- Co-Chair Therapeutics (SPPS 212C)
- Co-Chair Introduction to Oncology elective (SPPS 288)
- Collaborated with MCC nursing colleagues to develop and implement a chemotherapy class for cancer patients at MCC.
- Collaborated with anoncology pharmacy colleague, to develop a succinct toxicity checklist that utilizes the EPIC EMR to help providers effectively and efficiently assess a patient receiving immunotherapy for immune-mediated toxicities over the course of treatment.
- Working closely with cancer center and pharmacy leadership to expand oncology clinical pharmacy services at MCC.
- Wilhelm K et al. (2013) The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. J Oncol Pharm Pract 0:1-6.
- Saunders IM, et al. (2014) Topical Cidofovir–Induced Acute Kidney Injury in Two Severely Immunocompromised Patients with Refractory Multidrug-Resistant Herpes Simplex Virus Infections. J Oncol Pharm Pract, 0:1-7.
- Saliba RM et al (2015) General and Virus-Specific Immune Cell Reconstitution Following Double Cord Blood Transplantation. Biology of Blood and Marrow Transplantation 21:1284-90.
- Nightingale G, et al (2017) Hematology/Oncology Pharmacy Association Entry-level Competencies Task Force Response Statement to the 2016 American College of Clinical Pharmacy Pharmacotherapy Didactic Curriculum Toolkit. Pharmacotherapy 37(5):e30-e31
- Developing service interventions that will improve clinical outcomes for patients with cancer.
- Developing clinical practices that will improve appropriate medication prescribing and medication adherence for patients with cancer.